Collectively, these data reveal that ARL5B drives lipid synthesis and tumor progression via ROCK1‐mediated activation of SREBP1, providing mechanistic insights into how metabolic alterations fuel ESCC aggressiveness. The gene discussed is ARL5B; the disease is neoplasm.